全球生物类同市场预计将从2025年的32.9B上升到2034年的210.4B,其驱动因素是专利到期和对负担得起的治疗的需求,印度正在成为关键的生产者。 The global biosimilars market is expected to surge from $32.9B in 2025 to $210.4B by 2034, driven by patent expirations and demand for affordable treatments, with India emerging as a key producer.

全球生物类市场预计将从2025年的329亿美元增长到2034年的2 104亿美元,其驱动因素是专利到期、慢性病不断上升和对负担得起的治疗的需求。 The global biosimilars market is set to grow from $32.9 billion in 2025 to $210.4 billion by 2034, driven by patent expirations, rising chronic diseases, and demand for affordable treatments. 印度正在成为一个主要角色,其生物类同市场预计到2033年将达到59亿美元,其动力来自强劲的制造业、成本效益和超过135项核准。 India is emerging as a major player, with its biosimilars market projected to reach $5.9 billion by 2033, fueled by strong manufacturing, cost efficiency, and over 135 approvals. Biocon和Reddy博士等公司正在扩大全球出口,尽管监管障碍依然存在。 Companies like Biocon and Dr. Reddy’s are expanding global exports, though regulatory hurdles remain. 北美洲是目前价值为1.74万亿美元的更广泛的医药市场的主要市场,生物生物学创新和人工智能加速了药物开发。 North America leads the broader pharmaceutical market, now valued at $1.74 trillion, with innovation in biologics and AI accelerating drug development.